There is one clinical trial.
This is a Phase 2 trial to evaluate the efficacy and safety of intravenous (IV) infusions of
pamrevlumab as compared to placebo in hospitalized subjects with acute COVID-19 disease.
Primary Outcomes
Measure: Proportion of subjects who never received mechanical ventilation and/or ECMO and alive Time: Baseline to Day 28
Secondary Outcomes
Measure: Proportion of subjects alive, discharged home, and not on supplemental oxygen Time: Baseline to Day 28
Measure: Time to recovery based on a Modified 8-Point Ordinal Scale Time: Baseline to Day 28
Measure: Days in ICU/CCU (either on or off mechanical ventilation and/or ECMO) Time: Baseline to Day 28
Measure: Days on mechanical ventilation and/or ECMO Time: Baseline to Day 28
Measure: Time to death from any cause Time: Baseline to Day 28
Measure: Changes in PaO2/FiO2 ratio, both as categorical and continuous variable Time: Baseline to Day 28
Measure: Change in (non-invasive) oxygen supplementation requirements Time: Baseline to Day 28